B12 injections are contraindicated for individuals with Lebers hereditary optic neuropathy, severe kidney disease, known cobalt or cobalamin allergy, and polycythemia vera
CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.2 If approved, CagriSema would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment
This medicine has been shown to reduce blood glucose concentration, fasting plasma glucose concentrations, and postprandial glucose excursions
When it comes to shedding those extra pounds, two heavyweight contenders have taken the spotlight Semaglutide and Tirzepatide (Mounjaro)
Personalize Plans: Understand that each client is different